Clinical Trials

Arrowhead Pharmaceuticals secures $10m milestone payment from Amgen

Arrowhead Pharmaceuticals has secured a $10m milestone payment from Amgen, following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study.

Karuna raises $42m to advance KarXT into phase 2 study

Clinical-stage drug development firm Karuna Pharmaceuticals has completed $42m Series A financing round to advance selective muscarinic receptor agonist program into phase 2 study.

Celtaxsys’ CF drug acebilustat reduces pulmonary exacerbations in phase 2 trial

Celtaxsys' cystic fibrosis (CF) drug acebilustat has showed clinically meaningful improvements in pulmonary exacerbations in the phase 2 Empire-CF trial.

Investigator-initiated phase 2 trial to expand clinical evaluation of GKT831 into additional fibrotic disorder

Genkyotex said that US National Institutes of Health (NIH) has awarded an $8.9m grant to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program to assess the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF).

Emergent starts phase 1 trial of Zika virus immune globulin therapeutic

Emergent BioSolutions has initiated a phase 1 clinical study to assess the safety and pharmacokinetics of its anti-Zika virus immune globulin ZIKV-IG, which is being developed as a therapeutic intervention against Zika virus disease.

RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study

RedHill Biopharma’s RHB-104 orally-administered antibiotic combination therapy has achieved its primary endpoint and key secondary endpoints in phase III Crohn’s disease study.

Destiny Pharma’s XF-73 succeeds in phase 1 skin irritation study

Destiny Pharma, a UK-based clinical stage biotechnology company, has reported positive data for its synthetic antimicrobial drug XF-73 from a phase 1 skin irritation study.

Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial

Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial.

Chi-Med starts phase Ib/II trial of sulfatinib in NET and BTC patients

Hutchison China MediTech (Chi-Med) has commenced a phase Ib/II proof-of-concept study in the US to evaluate its small molecule angio-immuno kinase inhibitor sulfatinib in pancreatic neuroendocrine tumors (NET) and biliary tract cancer (BTC).